Webinar: R&D EXPENDITURE OPTIMIZATION-AN EMPIRICAL APPROACH TO R&D EXPENDITURE
Sponsored by: Thomson Reuters
Focused on:
Date: 6th April
Days old: 5054
Time: 3pm GMT / 10am ET
R&D EXPENDITURE OPTIMIZATION-AN EMPIRICAL APPROACH TO R&D EXPENDITURE
Join Thomson Reuters Life Sciences Consulting for a roundtable discussion on rational approaches to pharmaceutical R&D investment. A panel of thought leaders from the Thomson Reuters Life Sciences Consulting team have recently lead a discussion on current trends in R&D investment, current methodologies, and potential developments for the future. Pharmaceutical companies are suffering from declining R&D output and rising costs. Increasingly organizations are being challenged to justify their R&D expenditure. Despite increased costs, the pharmaceutical industry is still failing to meet expectations of regulators or the markets. Companies are now looking for alternative approaches to focus R&D investment and portfolios in commercially viable areas.
Thomson Reuters Life Sciences Consulting has worked with pharmaceutical companies to understand the most appropriate allocation of R&D expenditure based on an empirical, metric driven approach. In this webinar the approach, metrics, and key considerations will be discussed, with the goal of sharing with you a logical approach to pharmaceutical cost and resource allocation.
Presented by
HANS POULSEN,
Head of Thomson Reuters Life Sciences Consulting
Hans Poulsen has over 14 years' experience consulting to the pharmaceutical, life sciences and healthcare sectors. Hans started his career as a Project Manager with DataEdge, where he developed a number of industry leading performance benchmarking databases of clinical protocol and investigator performance. Hans subsequently joined Accenture's Global Health & Life Sciences practice where he focused on growth & innovation, new product development, and strategic and operational R&D topics with the global pharmaceutical industry. Hans holds a B.Sc. in Economics & Business Administration and an MBA in Finance (Dean's list).
DR. PHILIP SPEARPOINT,
Senior Consultant, Thomson Reuters Life Sciences Consulting Team
Dr. Philip Spearpoint has over 7 years' experience in the pharmaceutical and healthcare sectors. Philip started his career in academia working on antiviral therapy for pandemic influenza, before moving into consulting. Philip worked in Accenture's Health and Life Sciences practice with a number of global pharmaceutical clients. Philip's areas of focus include business strategy, customer relationship management, process reengineering, benchmarking and benefits realization for major pharmaceutical and biotechnology clients. Philip has a PhD in pandemic influenza from University College London and a B.Sc. in microbiology from the University of Manchester.
Key Learning Objectives
- Past and present trends in pharmaceutical R&D productivity and how this relates to R&D expenditure
- The current state of return on R&D investment based on a recent joint study between Deloitte and Thomson Reuters
- Methods for investigating new areas of opportunity - the approach, potential metrics to use, and the importance of scientific understanding in successful commercial development
- Future scenarios for the R&D function in the pharmaceutical industry, and what impact these new strategies may have
Audience
- CEO - EL Medical Consulting
- VP Clinical Operations - SuperGen
- Managing Director - ATI Pharmaceutica
- Director - Takeda
- Director - Astrazeneca
- Director - Microsoft